- Conditions
- Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
- Interventions
- SNP analysis
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,834
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma, Carcinoma, Non-Small- Cell Lung
- Interventions
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Atopic Dermatitis
- Interventions
- BRT-FC-83C
- Device
- Lead sponsor
- Biomed Research & Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Colorado Springs, Colorado
- Conditions
- Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- ENV-294, Placebo
- Drug
- Lead sponsor
- Enveda Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Current standard eczema treatment and standard pillow at night, Chillow cooling pillow
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Intermittent Porphyria
- Interventions
- givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
- Interventions
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
- Interventions
- Tralesinidase alfa (TA)
- Drug
- Lead sponsor
- Spruce Biosciences
- Industry
- Eligibility
- 12 Months and older
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Atopic Dermatitis
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 10
- States / cities
- Tampa, Florida • Sandy Springs, Georgia • Rockville, Maryland + 7 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Setrusumab
- Biological
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- Oklahoma Medical Research Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 2,356 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Atopic Dermatitis
- Interventions
- Ruxolitinib, Vehicle Cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Alpelisib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Curcumin, Placebo
- Dietary Supplement
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Wrinkle
- Interventions
- BTL-785-7
- Device
- Lead sponsor
- BTL Industries Ltd.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Youngstown, Ohio
- Conditions
- Dermatitis Atopic
- Interventions
- dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 14 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Denver, Colorado • St Louis, Missouri • New York, New York
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema
- Interventions
- ENS-002
- Biological
- Lead sponsor
- Concerto Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Beverly, Massachusetts • Austin, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Difamilast, Placebo
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
- Conditions
- Gyrate Atrophy
- Interventions
- Gene therapy
- Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Familial Cold Autoinflammatory Syndrome
- Interventions
- DFV890
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Mucopolysaccharidosis II
- Interventions
- JR-141, Idursulfase, JR-141 or Idursulfase
- Drug
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- Not listed
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Oakland, California • Chicago, Illinois + 4 more
- Conditions
- Atopic Dermatitis
- Interventions
- ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more